23 Feb MEDIPOST
Antonio Lee, Global President
Rockville, MD
(078160 KOSDAQ)
MEDIPOST found in 2000, is a fully integrated regenerative medicine biopharmaceutical company with integrated capabilities across cord blood banking, stem cell research, GMP manufacturing, clinical development and commercialization, with a strong focus on allogeneic umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) therapeutics. MEDIPOST has successfully commercialized CARTISTEM®, the world’s first regulatory-approved allogeneic umbilical cord blood-derived MSC therapeutic for knee osteoarthritis. Since its approval in 2012, more than 37,000 patients have received CARTISTEM® treatment in South Korea, generating extensive real-world clinical data. Recently, positive topline data from the pivotal Phase III study in Japan was announced in May 2026, while the Phase III study in the U.S. & Canada has recently started enrolling patients in February 2026. MEDIPOST is also developing several late-stage hUCB-MSC pipelines including SMUP-IA (an intra-articular injectable early-stage OA treatment) and PNEUMOSTEM® (prophylactic treatment for Broncho-Pulmonary Dysplasia – rare indication for prematurely-born infants).